未名醫藥(002581.SZ):總經理辭職
格隆匯 4 月 11日丨未名醫藥(002581.SZ)公佈,公司董事會收到公司董事長出具的關於同意丁學國辭去公司總經理職務的函。至此,丁學國同時也將不再擔任公司全資子公司廈門未名生物醫藥有限公司總經理職務、公司控股子公司天津未名生物醫藥有限公司董事長、經理職務。
截止公吿日,丁學國未持有公司股份。即日起,根據《公司章程》第一百二十八條規定,由聯席總經理履職。公司董事會對丁學國在任職期間為公司所作的貢獻表示衷心感謝!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.